Cheson, BD, Bennett, JM, Kopecky, KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642–9.CrossRefGoogle Scholar

Freireich, EJ, Gehan, EA, Sulman, D, et al. The effect of chemotherapy on acute leukemia in the human. J Chronic Dis 1961;14:593–608.CrossRefGoogle ScholarPubMed

Bradstock, KF, Janossy, G, Tidman, N, et al. Immunological monitoring of residual disease in treated thymic acute lymphoblastic leukemia. Leuk Res 1981;5:301–9.CrossRefGoogle Scholar

Walter, RB, Kantarjian, HM, Huang, X, et al. Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. J Clin Oncol 2010;28:1766–71.CrossRefGoogle Scholar

Chen, X, Xie, H, Bohm, C, et al. The relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. J Clin Oncol 2015;33:1258-64.Google ScholarPubMed

Freeman, SD, Virgo, P, Couzens, S, et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patient with acute myeloid leukemia. J Clin Oncol 2013;31:4123–31.CrossRefGoogle ScholarPubMed

Kang, H, Chen, I-M, Wilson, CS, et al. Gene expression classifiers for relapse-free survival and minimal residual disease improve risk-classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. Blood 2010;115:1394–405.CrossRefGoogle ScholarPubMed

Yang, JJ, Cheng, C, Devidas, M, et al. Genome-wide association study identifies Germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood 2012;120:4197–204.Google ScholarPubMed

Beldjord, K, Chevret, S, Asnafi, V, et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood 2014;123:3739–49.CrossRefGoogle ScholarPubMed

Vora, A, Frost, L, Goodeve, A, et al. Late relapsing childhood lymphoblastic leukemia. Blood 1998;92:2334–7.CrossRefGoogle ScholarPubMed

Ommen, HB, Schnittger, S, Jovanovic, JV, et al. Strikingly different molecular relapse Grimwadekinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Blood 2010;115:198–205.CrossRefGoogle ScholarPubMed

Parker, C, Waters, R, Leighton, C, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukemia (ALL R3): an open-label randomized trial. The Lancet 2010;376:2009–17.CrossRefGoogle Scholar

Butturini, A, Klein, J, Gale, RP. Modeling minimal residual disease (MRD)-testing. Leuk Res 2003;27:293–300.CrossRefGoogle ScholarPubMed

Mullighan, CG, Su, X, Zhang, J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009;360:470–80.CrossRefGoogle ScholarPubMed

van der Veer, A, Waanders, E, Pieters, R, et al. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood 2013;122:2622–9.CrossRefGoogle Scholar

Roberts, KG, Li, Y, Payne-Turner, D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 2014;371:1005–15.CrossRefGoogle ScholarPubMed

Lee, S, Kim, D-W, Cho, B-S, et al. Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 2012;26:2367–74.CrossRefGoogle ScholarPubMed

Ravandi, F, Jorgensen, JL, Thomas, DA, et al. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood 2013;122:1214–21.CrossRefGoogle ScholarPubMed

Jeha, S, Coustan-Smith, E, Pei, D, et al. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 2014;120:1514–9.CrossRefGoogle ScholarPubMed

Helgestad, J, Rosthøj, S, Johansen, P, et al. Bone marrow aspiration technique may have an impact on therapy stratification in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2011;57:224–6.CrossRefGoogle Scholar

Paietta, E. Minimal residual disease in AML: coming of age. Hematol Am Soc Hematol Educ Program 2012;2012:35–42.CrossRefGoogle ScholarPubMed

Paietta, E. Minimal residual disease in acute leukaemia: a guide to precision medicine ready for prime time? In Treatment Strategies Haematology, Vol 4, issue 2, 2014, pp 45-48.Google Scholar

Grimwade, D, Freeman, SD. Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”? Blood 2014;124:3345–55.CrossRefGoogle ScholarPubMed

Loken, MR, Chu, S-C, Fritschle, W, et al. Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses. Cytometry Part B (Clin Cytometry) 2009;76B:27–36.CrossRefGoogle Scholar

Buccisano, F, Maurillo, L, Del Principe, MI, et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood 2012;119:332–41.CrossRefGoogle ScholarPubMed

Loken, MR, Alonzo, TA, Pardo, L, et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children’s Oncology Group. Blood 2012;120:1581–8.CrossRefGoogle ScholarPubMed

Inaba, H, Coustan-Smith, E, Cao, X, et al. Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. J Clin Oncol 2012;30:3625–32.CrossRefGoogle ScholarPubMed

Campana, D, Coustan-Smith, E. Measurements of treatment response in childhood acute leukemia. Korean J Hematol 2012;47:245–54.CrossRefGoogle ScholarPubMed

McKenna, RW, Washington, LT, Aquino, DB, et al. Immunophenotypic analysis of hematogones (B-lymphocyte precursor) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood 2001;98:2498–507.CrossRefGoogle Scholar

Sevilla, DW, Colovai, AI, Emmons, FN, et al. Hematogones: a review and update. Leuk Lymphoma 2010;51:10–19.CrossRefGoogle Scholar

Sedek, L, Bulsa, J, Sonsala, A, et al. The immunophenotypes of blast cells in B-cell precursor acute lymphoblastic leukemia: how different are they from their normal counterparts? Cytometry B Clin Cytom 2014;86:329–39.CrossRefGoogle ScholarPubMed

Loken, MR, Alonzo, TA, Pardo, L, et al. Multidimensional flow cytometry significantly improves upon the morphologic assessment of post-induction marrow remission status-comparison of morphology and multidimensional flow cytometry: a report from the Children’s Oncology Group AML Protocol AAML0531. Blood 2012;120(8):1581–8.Google Scholar

Grimwade, D, Tallman, M. Should minimal residual disease monitoring be the standard of care for all patients with acute promyelocytic leukemia? Leuk Research 2011;35:3–7.CrossRefGoogle ScholarPubMed

Wang, F, Travis, J, DeLaBarre, B, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 2013;340:622–6.CrossRefGoogle ScholarPubMed

Gaipa, G, Cazzaniga, G, Valsecchi, MG, et al. Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia. Haematologica 2012;97:1582–93.CrossRefGoogle ScholarPubMed

Van der Velden, VHJ, Cazzaniga, G, Schrauder, A, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007;21:604–11.CrossRefGoogle ScholarPubMed

van Dongen, JJM. EuroFlow Educational Book 2012; Rotterdam: Macmillan.Google Scholar

Boeckx, N, Willemse, MJ, Szczepanski, T, et al. Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia. Leukemia 2002;16:368–75.CrossRefGoogle ScholarPubMed

Warren, EH, Matsen, FA IV, Chou, J. High-throughput sequencing of B- and T-lymphocyte antigen receptors in hematology. Blood 2013;122:19–22.CrossRefGoogle ScholarPubMed

Faham, M, Zheng, J, Moorhead, M, et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2012;120:5173–80.Google ScholarPubMed

Martinez-Lopez, J, Lahuerta, JJ, Pepin, F, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood 2014;123:3073–9.CrossRefGoogle ScholarPubMed

UK NEQAS. www.ukneqas.org.ukGoogle Scholar

Wood, B. Flow cytometric assessment of MRD. Presented at the FDA Public Workshop on Minimal Residual Disease, FDA White Oak Campus, Silver Spring, MD, April 18, 2012.Google Scholar

Wood, BL. Flow cytometric monitoring of residual disease in acute leukemia. In Czader, M. (ed) Hematological Malignancies: Methods in Molecular Biology, vol 999. 2013; New York: Springer, pp. 123–36.Google Scholar

Chevallier, P, Robillard, N, Ayari, S, et al. Persistence of CD33 expression at relapse in CD33(+) acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease. Br J Haematol 2008;143:744–6.CrossRefGoogle ScholarPubMed

Chu, PG, Chen, YY, Molina, A, et al. Recurrent B-cell neoplasms after Rituximab therapy: an immunophenotypic and genotypic study. Leuk Lymphoma 2002;43:2335–41.CrossRefGoogle ScholarPubMed

Topp, MS, Kufer, P, Gökbuget, N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011;29:2493–8.CrossRefGoogle ScholarPubMed

Campana, D. Should minimal residual disease monitoring in acute lymphoblastic leukemia be standard of care? Curr Hematol Malig Rep 2012;7:170–7.CrossRefGoogle ScholarPubMed

van Dongen, JJM, Lhermitte, L, Böttcher, S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012;26:1908–75.CrossRefGoogle ScholarPubMed

Zeijlemaker, W, Gratama, JW, Schuurhuis, GJ. Tumor heterogeneity makes AML a “moving target” for detection of residual disease. Cytometry B Clin Cytom 2014;86:3–14.CrossRefGoogle ScholarPubMed

Coustan-Smith, E, Song, G, Clark, C, et al. New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2011;117:6267–76.CrossRefGoogle ScholarPubMed

Langebrake, C, Brinkmann, I, Teigler-Schlegel, A, et al. Immunophenotypic differences between diagnosis and relapse in childhood AML: implications for MRD monitoring. Cytometry B Clin Cytom 2005;63B:1–9.CrossRefGoogle Scholar

Macedo, A, San Miguel, JF, Vidriales, MB, et al. Phenotypic changes in acute myeloid leukemia: implications in the detection of minimal residual disease. J Clin Pathol 1996;49:15–18.CrossRefGoogle ScholarPubMed

Brϋggemann, M, Raff, T, Kneba, M. Has MRD monitoring superseded other prognostic factors in adult ALL? Blood 2012;120:4470–81.CrossRefGoogle Scholar

Wu, D, Emerson, RO, Sherwood, A, et al. Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH. Clin Cancer Res 2014;20:4540–8.CrossRefGoogle Scholar

Thol, F, Kölking, B, Damm, F, et al. Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations. Genes Chromosom Cancer 2012;51:689–95.CrossRefGoogle ScholarPubMed

Bachas, C, Schuurhuis, GJ, Assaraf, YG, et al. The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse. Leukemia 2012;26:1313–20.CrossRefGoogle ScholarPubMed

Hou, H-A, Kuo, Y-Y, Liu, C-Y, et al. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood 2012;119:559–68.CrossRefGoogle ScholarPubMed

Im, AP, Sehgal, AR, Carroll, MP, et al. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia 2014;28:1774–83.CrossRefGoogle ScholarPubMed

Salipante, SJ, Fromm, JR, Shendure, J, et al. Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing. Mod Pathol 2014;27:1438–46.CrossRefGoogle ScholarPubMed

Stow, P, Key, L, Chen, X, et al. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood 2010;115:4657–63.CrossRefGoogle ScholarPubMed

Maurillo, L, Buccisano, F, Del Principe, MI, et al. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol 2008;26:4944–51.CrossRefGoogle ScholarPubMed

Rubnitz, JE, Inaba, H, Dahl, G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukemia: results of the AML02 multicentre trial. The Lancet 2010;11:543–52.Google ScholarPubMed

Terwijn, M, van Putten, WLJ, Kelder, A, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: Data from the HOVON/SAKK AML 42A study. J Clin Oncol 2013;31:3889–97.CrossRefGoogle ScholarPubMed

Ganzel, C, Sun, Z, Gönen, M, et al. Minimal residual disease assessment by flow cytometry in AML is an independent prognostic factor even after adjusting for cytogenetic/molecular abnormalities. Blood 2014;124:1016.CrossRefGoogle Scholar

Fernandez, HF, Sun, Z, Yao, X, et al. Anthracycline dose intensification in acute myeloid leukemia: Results of ECOG Study E1900. N Engl J Med 2009;361:1249–59.CrossRefGoogle Scholar

Perea, G, Lasa, A, Aventin, A, et al. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]. Leukemia 2006;20:87–94.CrossRefGoogle Scholar

Miyamoto, T, Weissman, IL, Akashi, K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci USA 2000;97:7521–6.CrossRefGoogle ScholarPubMed

Corces-Zimmerman, MR, Hong, W-J, Weissman, IL, et al. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci USA 2014;111:2548–53.CrossRefGoogle ScholarPubMed

Shlush, LI, Zandi, S, Mitchell, A, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014;506:328–33.CrossRefGoogle ScholarPubMed

Bodini, M, Ronchini, C, Giacò, L, et al. The hidden genomic landscape of acute myeloid leukemia: subclonal structure revealed by undetected mutations. Blood 2015;125:600–5.CrossRefGoogle ScholarPubMed

Will, B, Steidl, U. Multi-parameter fluorescence-activated cell sorting and analysis of stem and progenitor cells in myeloid malignancies. Best Pract Res Clin Haematol 2010;23:391–401.CrossRefGoogle ScholarPubMed

Ebinger, M, Witte, K-E, Ahlers, J, et al. High frequency of immature cells at diagnosis predicts high minimal residual disease level in childhood acute lymphoblastic leukemia. Leuk Res 2010;34:1139–42.CrossRefGoogle ScholarPubMed

Terwijn, M, Kelder, A, Snel, AN, et al. Minimal residual disease detection defined as the malignant fraction of the total primitive stem cell compartment offers additional prognostic information in acute myeloid leukemia. Int J Lab Hem 2012;34:432–41.CrossRefGoogle Scholar

Gerber, JM, Smith, BD, Ngwang, B, et al. A clinically relevant population of leukemic CD34⁺CD38^- cells in acute myeloid leukemia. Blood 2012;119:3571–7.CrossRefGoogle ScholarPubMed

Roug, AS, Larsen, HØ, Nederby, L, et al. hMICL and CD123 in combination with a CD45/CD34/CD117 backbone – a universal marker combination for the detection of minimal residual disease in acute myeloid leukemia. Br J Haematol 2014;164:212–22.CrossRefGoogle Scholar

DiGiuseppe, JA. CD34+/CD38- cells and minimal residual disease in childhood lymphoblastic leukemia. Leuk Res 2010;34:1125–6.CrossRefGoogle ScholarPubMed

Aoki, Y, Watanabe, T, Saito, Y, et al. Identification of CD34⁺ and CD34^- leukemia-initiating cells in MLL-rearranged human acute lymphoblastic leukemia. Blood 2014;125:967–80.Google ScholarPubMed

Mullighan, CG, Phillips, LA, Su, X, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 2008;322:1377–80.CrossRefGoogle ScholarPubMed

Notta, F, Mullighan, CG, Wang, JC, et al. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 2011;469:362–7.CrossRefGoogle ScholarPubMed

Clappier, E, Gerby, B, Sigaux, F, et al. Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J Exp Med 2011;208:653–61.CrossRefGoogle Scholar

Klco, JM, Spencer, DH, Miller, CA, et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell 2014;25:379–92.CrossRefGoogle ScholarPubMed

Inaba, H, Greaves, M, Mullighan, CG. Acute lymphoblastic leukemia. Lancet 2013;381:1943–55.CrossRefGoogle Scholar

Chan, SM, Majeti, R. Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia. Int J Hematol 2013;98:648–57.CrossRefGoogle ScholarPubMed

Peloquin, GL, Chen, YB, Fathi, AT. The evolving landscape in the therapy of acute myeloid leukemia. Protein Cell 2013;4:735–46.CrossRefGoogle ScholarPubMed

Li, KK, Luo, LF, Shen, Y, et al. DNA methyltransferases in hematologic malignancies. Semin Hematol 2013;50:48–60.CrossRefGoogle ScholarPubMed

Barreyro, L, Will, B, Bartholdy, B, et al. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood 2012;120:1290–8.CrossRefGoogle ScholarPubMed

Askmyr, M, Ågerstam, H, Hansen, N, et al. Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. Blood 2013;121:3709–13.CrossRefGoogle ScholarPubMed

Schultz, KR, Bowman, WP, Aledo, A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a Children’s Oncology Group study. J Clin Oncol 2009;27:5175–81.CrossRefGoogle ScholarPubMed

Manabe, A, Kawasaki, H, Shimada, H, et al. Imatinib use immediately before stem cell transplantation in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: Results from Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Study Ph+ALL04. Cancer Med 2015; Jan 31. doi: 10.1002/cam4.383. [Epub ahead of print]CrossRefGoogle Scholar

Lee, HJ, Thompson, JE, Wang, ES, Wetzler, M. Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 2011;117:1583–94.CrossRefGoogle ScholarPubMed

Bachanova, V, Marks, DI, Zhang, M-J, et al. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: Impact of tyrosine kinase inhibitor and minimal residual disease. Leukemia 2014;28:658–65.CrossRefGoogle ScholarPubMed

Wetzler, M, Watson, D, Stock, W, et al. Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance). Haematologica 2014;99:111–5.CrossRefGoogle ScholarPubMed

Schenk, TM, Keyhani, A, Böttcher, S, et al. Multilineage involvement of Philadelphia chromosome positive acute lymphoblastic leukemia. Leukemia 1998;12:666–74.CrossRefGoogle ScholarPubMed

Rovida, E, Peppicelli, S, Bono, S, et al. The metabolically-modulated stem cell niche: a dynamic scenario regulating cancer cell phenotype and resistance to therapy. Cell Cycle 2014;13:3169–75.CrossRefGoogle ScholarPubMed

Ribera, J-M. Optimal approach to treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: how to best use all the available tools. Leuk Lymphoma 2013;54:21–7.CrossRefGoogle ScholarPubMed

Herrmann, H, Sadovnik, I, Cerny-Reiterer, S, et al. Dipeptidylpeptidase IV (CD26) defines leukemic stem cells in chronic myeloid leukemia. Blood 2014;123:3951–62.CrossRefGoogle ScholarPubMed

Pfeifer, H, Wassmann, B, Bethge, W, et al. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. Leukemia 2013;27:1254–62.CrossRefGoogle ScholarPubMed

Orgel, E, Tucci, J, Alhushki, W, et al. Obesity is associated with residual leukemia following induction therapy for childhood B-precursor acute lymphoblastic leukemia. Blood 2014;124:3932–8.CrossRefGoogle ScholarPubMed

Ehsanipour, EA, Sheng, X, Behan, JW, et al. Adipocytes cause leukemia cell resistance to L-asparaginase via release of glutamine. Cancer Res 2013;73:2998–3006.CrossRefGoogle ScholarPubMed

Pramanik, R, Sheng, X, Ichihara, B, et al. Adipose tissue attracts and protects acute lymphoblastic leukemia cells from chemotherapy. Leuk Res 2013;37:503–9.CrossRefGoogle ScholarPubMed

Borowitz, MJ, Devidas, M, Hunger, SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood 2008;111:5477–85.CrossRefGoogle ScholarPubMed

Möricke, A, Reiter, A, Zimmermann, M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008;111:4477–89.CrossRefGoogle ScholarPubMed

Conter, V, Bartram, CR, Valsecchi, MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010;115:3206-14.CrossRefGoogle Scholar

Corbacioglu, A, Scholl, C, Schlenk, RF, et al. Prognostic impact of miminal residual disease in CBFB-MYH11-positive acute myeloid leukemia. J Clin Oncol 2010;28:3724–9.CrossRefGoogle Scholar

Zhu, H-H, Zhang, X-H, Qin, Y-Z, et al. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood 2013;121:4056–62.CrossRefGoogle ScholarPubMed

Jourdan, E, Boissel, N, Chevret, S, et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood 2013;121:2213–23.CrossRefGoogle ScholarPubMed

Liu Yin, JA, O’Brien, MA, Hills, RK, et al. Minimal residual disease monitoring by RT-qPCR in core-binding factor AML allows risk-stratification and predicts relapse: results of the UK MRC AML-15 trial. Blood 2012;120:2826–35.Google Scholar

Buccisano, F, Maurillo, L, Spagnoli, A, et al. Cytogenetic and molecular diagnostic characterization combined to post-consolidation minimal residual disease assessment by flow-cytometry improves risk stratification in adult acute myeloid leukemia. Blood 2010;116:2295–303.CrossRefGoogle Scholar

Gönen, M, Sun, Z, Figueroa, ME, et al. CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase III trial, E1900. Blood 2012;120:2297–306.CrossRefGoogle ScholarPubMed

Waanders, E, van der Velden, VHJ, van der Schoot, CE, et al. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia. Leukemia 2011;25:254–8.CrossRefGoogle ScholarPubMed

Geng, H, Brennan, S, Milne, TA, et al. Integrative epigenomic analysis of adult B-acute lymphoblastic leukemia identifies biomarkers and therapeutic targets. Cancer Discovery 2012;2:1004–23.CrossRefGoogle ScholarPubMed

Kobayashi, CI, Takubo, K, Kobayashi, H, et al. The IL-2/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells. Blood 2014;123:2540–9.CrossRefGoogle ScholarPubMed

Hagedorn, N, Acquaviva, C, Fronkova, E, et al. Submicroscopic bone marrow involvement in isolated extramedullary relapses in childhood acute lymphoblastic leukemia: a more precise definition of “isolated” and its possible clinical implications, a collaborative study of the Resistant Disease Committee of the International BFM study group. Blood 2007;110:4022–9.CrossRefGoogle ScholarPubMed

Patel, B, Rai, L, Buck, G, et al. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. Br J Haematol 2009;148:80–9.Google ScholarPubMed

Grimwade, D, Jovanovic, JV, Hills, RK, et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol 2009;27:3650–8.CrossRefGoogle ScholarPubMed

Sockel, K, Wermke, M, Radke, J, et al. Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse. Haematologica 2011;96:1568–70.CrossRefGoogle ScholarPubMed

Platzbecker, U, Wermke, M, Radke, J, et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 2012;26:381–9.CrossRefGoogle ScholarPubMed

Rubnitz, J, Inaba, H, Dahl, G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol 2010;11:543–52.CrossRefGoogle ScholarPubMed

O’Hear, C, Inaba, H, Punds, S, et al. Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. Cancer 2013;119:4036–43.Google ScholarPubMed

Annesley, CE, Brown, P. Novel agents for the treatment of childhood acute leukemia. Ther Adv Hematol 2015;6:61–79.CrossRefGoogle ScholarPubMed

Topp, M, Gökbuget, N, Zugmaier, G, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012;120:5185–7.CrossRefGoogle Scholar